Neupogen (Filgrastim)

Filgrastim binds to the granulocyte‑colony stimulating factor receptor on hematopoietic stem cells in the bone marrow. This binding activates intracellular signaling that promotes the proliferation, differentiation, and activation of neutrophil precursors, leading to an increased number of functional neutrophils in the bloodstream.

The dose of Neupogen is individualized by the prescribing clinician based on the patient’s weight, underlying condition, and response to therapy. Healthcare providers calculate the appropriate amount and frequency, and patients should follow the prescriber’s instructions without self‑adjusting the dose.

The safety of Neupogen in pregnancy and lactation has not been firmly established. It is classified as pregnancy category unknown, and use is generally reserved for situations where the potential benefit outweighs any potential risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks with their healthcare professional.

To order Neupogen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Neupogen (filgrastim) is a short‑acting recombinant G‑CSF, similar in efficacy to other filgrastim products but differs from long‑acting agents such as pegfilgrastim, which require less frequent dosing. Choice between products depends on clinical protocol, dosing convenience, cost considerations, and patient-specific factors.

Neupogen must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature, it may be used for a limited period as specified in the label, but should be returned to refrigeration promptly.

Neupogen is administered by subcutaneous injection, typically into the abdomen or thigh. The injection site should be rotated to minimize local irritation. Administration is performed by a qualified healthcare professional or trained patient under medical supervision, following aseptic technique and the prescriber’s dosing schedule.

Serious risks include splenic rupture, acute respiratory distress syndrome, severe allergic reactions (including anaphylaxis), capillary leak syndrome, and uncontrolled leukocytosis. Patients should be instructed to seek immediate medical attention if they experience sudden abdominal pain, difficulty breathing, severe rash, or unexplained swelling.

Neupogen should not be used in individuals with a known hypersensitivity to filgrastim or any of its excipients. Caution is also advised for patients with sickle‑cell disease, active splenomegaly, or those receiving concurrent colony‑stimulating factors, unless specifically directed by a physician.